Cabozantinib or Nivolumab Plus Ipilimumab as Treatment Options for Renal Cell Carcinoma
A review of data from the CABOSUN and CheckMate-214 trials to determine the use of targeted therapy in metastatic renal cell carcinoma.
Chemotherapy Foundation Symposium (CFS)
Ribociclib Plus Letrozole Prolongs PFS in Advanced Breast Cancer: A Secondary Analysis of MONALEESA-2
Although endocrine therapy has been the standard of care for HR+/HER2- breast cancer, cyclin-D and cyclin-dependent kinase (CDK) dysregulation-driven resistance to this treatment occurs at very high rates among patients.
Liquid Biopsies: An Emerging, Effective, Versatile Monitoring Modality in Lung Cancer
In lung cancer, it is critical to evaluate the resistance mechanisms so appropriate treatment can be administered.
First-line Osimertinib for EGFR-mutation Positive NSCLC
The discovery of molecular biomarkers and EGFR mutations have shifted the management of NSCLC from traditional cytotoxic chemotherapies towards precision medicine with TKIs.
The Role of Anti-PD-1 Immunotherapy in Advanced Triple-negative Breast Cancer
Breast cancer was previously thought to not be immunogenic in nature, but a subset of patients with breast cancer, primarily with triple negative disease, have exhibited robust levels of tumor infiltrating leukocytes.
Nivolumab Provides Long-term Benefit after Auto-HCT Classical Hodgkin Lymphoma
An interim analysis of a cohort in the CheckMate-205 study showed that nivolumab had an acceptable safety profile and demonstrated efficacy among patients with relapsed and refractory classical Hodgkin lymphoma after post-auto-HCT brentuximab vedotin.
Patient Clinical Features Should Be Sequentially Considered to Determine Optimal Treatment in CLL
In order to optimize therapeutic sequencing among patients with CLL, 5 patient aspects must be considered.
Studies That May Shift Treatment Paradigms in Gastric Cancer: A Review of Recent Trials
In 2017, new treatment approaches for patients with esophagogastric cancer have been investigated, including novel neoadjuvant regimens and immunotherapies.
Elotuzumab May Provide Greatest Sustained Relative PFS Benefit in Multiple Myeloma
Four recently approved treatment regimens have demonstrated a PFS benefit for patients with RRMM relative to Rd, but no head-to-head studies have been conducted.
Melatonin Analogues May Have Antitumor Properties in Melanoma and Breast Cancer
Previous studies have demonstrated that melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chemotherapy Foundation Symposium (CFS)
Loading... 
Loading...